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Atherosclerosis and liver inflammation <p>With increasing dietary cholesterol intake the liver switches from a mainly resilient to a predominantly inflammatory state, which is  associated with early lesion formation.</p>
Abstract
Background:  Increased dietary cholesterol intake is associated with atherosclerosis.
Atherosclerosis development requires a lipid and an inflammatory component. It is unclear where
and how the inflammatory component develops. To assess the role of the liver in the evolution of
inflammation, we treated ApoE*3Leiden mice with cholesterol-free (Con), low (LC; 0.25%) and
high (HC; 1%) cholesterol diets, scored early atherosclerosis and profiled the (patho)physiological
state of the liver using novel whole-genome and metabolome technologies.
Results: Whereas the Con diet did not induce early atherosclerosis, the LC diet did so but only
mildly, and the HC diet induced it very strongly. With increasing dietary cholesterol intake, the liver
switches from a resilient, adaptive state to an inflammatory, pro-atherosclerotic state. The liver
absorbs moderate cholesterol stress (LC) mainly by adjusting metabolic and transport processes.
This hepatic resilience is predominantly controlled by SREBP-1/-2, SP-1, RXR and PPARα. A further
increase of dietary cholesterol stress (HC) additionally induces pro-inflammatory gene expression,
including pro-atherosclerotic candidate genes. These HC-evoked changes occur via specific pro-
inflammatory pathways involving specific transcriptional master regulators, some of which are
established, others newly identified. Notably, several of these regulators control both lipid
metabolism and inflammation, and thereby link the two processes.
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Conclusion: With increasing dietary cholesterol intake the liver switches from a mainly resilient
(LC) to a predominantly inflammatory (HC) state, which is associated with early lesion formation.
Newly developed, functional systems biology tools allowed the identification of novel regulatory
pathways and transcriptional regulators controlling both lipid metabolism and inflammatory
responses, thereby providing a rationale for an interrelationship between the two processes.
Background
Atherosclerosis is a multifactorial disease of the large arteries
and the leading cause of morbidity and mortality in industri-
alized countries [1]. There is ample evidence that hypercho-
lesterolemia (that is, elevated plasma levels of low-density
lipoprotein (LDL) and very low-density lipoprotein (VLDL))
induced by genetic modification or enhanced intake of dietary
lipids is a major causative factor in atherogenesis [2,3]. It is
equally clear that from the very beginning of lesion formation,
atherogenesis requires an inflammatory component, which is
thought to drive the progression of the disease [4,5]. Indeed,
some of the variation in the rate of lesion progression in dif-
ferent individuals may relate to variations in their basal
inflammatory state [6,7]. However, while the inflammatory
processes in the complex evolution of the lesion from the
early fatty streak to a fibrous plaque are considered self-per-
petuating phenomena, the initial trigger and origin of the
inflammatory component in hypercholesterolemia remains
enigmatic [6,8].
Recent observations by us and others suggest that the liver
plays a key role in the inflammatory response evoked by die-
tary constituents (reviewed in [8,9]). For example, liver-
derived inflammation markers such as C-reactive protein
(CRP) and serum amyloid A (SAA) increase rapidly (within
days) after consumption of an excess amount of dietary lipids
[8,10], and thus by far precede the onset of early aortic lesion
formation [8]. These findings suggest that nutritional choles-
terol itself may contribute to the evolution of the inflamma-
tory component of atherogenesis. We postulate that pro-
atherogenic inflammatory factors originate at least partly
from the liver. We also hypothesize that these factors come
into play at high dietary cholesterol doses because of the
exponential rather than linear nature of the relationship
between cholesterol intake (measured as cholesterol plasma
levels) and atherosclerotic lesion size [11,12] as specified in
more detail in Additional data file 1.
In this study we sought evidence for the hypothesis that
inflammation and hypercholesterolemia are not separate fac-
tors, but closely related features of the same trigger, dietary
cholesterol. In particular, using a variety of newly developed
functional bioinformatics tools, we addressed the question of
how the liver responds to increasing dietary cholesterol loads
at the gene transcription level and analyzed how hepatic cho-
lesterol metabolism is linked to the hepatic inflammatory
response, including underlying regulatory mechanisms.
Notably, all analyses were performed at a very early stage of
the atherogenic process (that is, after 10 weeks of cholesterol
feeding) to limit potential feedback reactions from the vessel
wall.
An established model for cholesterol-induced atherosclero-
sis, ApoE*3Leiden transgenic (E3L) mice, allowed the appli-
cation of experimental conditions that mimic the human
situation: E3L mice display a lipoprotein profile similar to
that of humans suffering from dysbetalipoproteinemia and
develop atherosclerotic lesions that resemble human lesions
with regard to morphology and cellular composition [13,14].
E3L mice were exposed to increasing doses of dietary choles-
terol (as the only dietary variable modulated), and liver
genome and metabolome datasets were analyzed in a unique
context, that is, at the time point of first lesion development.
Advanced (functional) bioinformatical analysis allowed us to
merge metabolome and transcriptome datasets and to ana-
lyze pathways and biochemical processes comprehensively.
Recent advances in systems biology (for example, new biolog-
ical process software for network building and data mining)
have enabled us to discover significant relationships and to
identify transcriptional master regulators that control gene
alteration and are ultimately responsible for effects at the
process level.
Results
Effect of dietary cholesterol load on plasma lipids and 
early atherosclerosis
Treatment of female E3L mice with a cholesterol-free (Con),
a low-cholesterol (LC) or a high-cholesterol (HC) diet
resulted in total plasma cholesterol concentrations that stabi-
lized at 5.9 ± 0.3 mM, 13.3 ± 1.9 mM and 17.9 ± 2.4 mM,
respectively. The increase in plasma cholesterol in the LC and
HC groups was confined to the pro-atherogenic lipoprotein
particles VLDL and LDL (Figure 1a). High-density lipopro-
tein (HDL) levels and plasma triglyceride levels were compa-
rable between the groups (Figure 1a and Table 1). The plasma
levels of alanine aminotransferase (ALAT) and aspartate ami-
notransferase (ASAT), two markers of liver function, were
comparable in the Con and LC groups and slightly elevated in
the HC group.
After 10 weeks of dietary treatment, the animals were eutha-
nized to score early atherosclerosis. Longitudinally opened
aortas of the Con and LC groups were essentially lesion-free
(en face oil red O-staining), while aortas of the HC group
already contained lesions (not shown). Consistent with thehttp://genomebiology.com/2007/8/9/R200 Genome Biology 2007,     Volume 8, Issue 9, Article R200       Kleemann et al. R200.3
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presence of atherosclerosis in the HC group, the vascular
inflammation marker E-selectin was elevated only in this
group (Table 1). Early onset of atherosclerosis was analyzed in
more detail in the valve area of the aortic root (Figure 1b), a
region in which lesions develop first [15]. The total cross-sec-
tional lesion area under basal conditions was 1,900 ± 900
μm2 (Con group; Figure 1c). Compared to the Con group, the
lesion area was relatively moderately increased in the LC
group (4.2-fold; P < 0.05) and strongly increased in HC (19.5-
fold; P < 0.05), confirming the exponential rather than linear
relationship between total plasma cholesterol levels and the
lesion area.
Next, lesions in the aortic root were graded according to the
classification of the American Heart Association. Under con-
trol conditions (Con); only about 10% of the aortic segments
contained lesions, all of which were very mild type I lesions
not identified by en face staining (Figure 1d). In the LC group,
more (40%) aortic segments showed lesions, of which 38%
were mild type I-III lesions and 2% were severe type IV
lesions. In the HC group, 81% of the aortic segments dis-
played lesions, most of which were mild lesions (76% type I-
III lesions; 5% type IV). The predominance of mild-type
lesions confirms an early stage of atherosclerotic disease in all
groups. Notably, a positive association was observed between
the cross-sectional lesion area and the plasma levels of SAA,
an inflammation marker formed in liver. SAA was signifi-
cantly elevated in the HC group, pointing to a hepatic inflam-
matory response to cholesterol feeding (Table 1) that is
associated with early atherosclerotic lesion formation.
Analysis of the hepatic gene response to increasing 
doses of dietary cholesterol
To get insight into the complex traits underlying the
(patho)physiological response of the liver to dietary choles-
terol, whole-genome and metabolome measurements were
made. Compared to the Con group, a relatively small number
of genes (551) significantly changed with LC treatment (Fig-
ure 2). HC treatment modulated most (440 out of 551) of
these genes and, additionally, affected 1,896 other genes. The
individual gene expression profiles within a treatment group
were very similar and formed clusters as confirmed by hierar-
chical clustering analysis (not shown). Differences in gene
expression between the treatment groups were validated and
confirmed for a selected group of genes by RT-PCR (Addi-
tional data file 2).
Standard Gene Ontology (GO) biological process annotation
allowed categorization of 52% of the differentially expressed
genes based on their biological function (Table 2). LC treat-
ment predominantly affected genes belonging to lipid and
lipoprotein metabolism, protein metabolism, carbohydrate
metabolism, energy metabolism and transport. HC treatment
affected the same GO groups but, additionally, also genes rel-
evant to immune and inflammatory responses, cell prolifera-
tion, apoptosis, cell adhesion and cytoskeleton integrity
(Table 2 and Additional data file 3).
To refine the liver transcriptome data analysis and to define
which biological processes are switched on/off with increas-
ing dietary cholesterol loads, we performed gene enrichment
analysis in four different functional ontologies: biological
processes, canonical pathway maps, cellular processes and
disease categories using MetaCore™. This allowed us to ana-
lyze functionally related genes (for example, genes belonging
to a specific biochemical process) as a whole. Table 3 summa-
rizes the significantly changed biological processes for the LC
and HC groups. Four key ('master') process categories were
affected by cholesterol feeding: lipid metabolism; carbohy-
drate and amino acid metabolism; transport; immune and
inflammatory responses.
Table 1
Effects of dietary cholesterol on plasma lipids and inflammation markers
Con LC HC
Body weight (start) (g) 20.3 ± 1.5 20.8 ± 1.5 20.6 ± 0.9
Body weight gain (g) 0.4 ± 0.7 0.7 ± 0.8 0.6 ± 0.5
Food intake (g/day) 2.6 ± 0.2 2.9 ± 0.3* 2.5 ± 0.2†
Plasma cholesterol (mM) 5.9 ± 0.3 13.3 ± 1.9* 17.9 ± 2.4*†
Plasma triglyceride (mM) 1.7 ± 0.4 2.3 ± 0.3 2.1 ± 0.7
Plasma E-selectin (μg/ml) 44.3 ± 2.3 44.3 ± 6.3 55.1 ± 8.5*†
Plasma SAA (μg/ml) 2.8 ± 0.6 4.7 ± 1.7 8.3 ± 2.7*†
Plasma ALAT (U/mL) 48 ± 44 45 ± 22 75 ± 23
Plasma ASAT (U/mL) 260 ± 123 237 ± 57 569 ± 221*†
Three groups of female E3L mice were fed either a cholesterol-free (Con) diet or the same diet supplemented with 0.25% (LC) or 1.0% (HC) w/w 
cholesterol. Listed are the average body weight at the start (t = 0) of the experimental period together with the body weight gain, the average daily 
food intake and the average plasma levels of cholesterol, triglycerides, E-selectin, serum amyloid A (SAA), alanine aminotransferase (ALAT) and 
aspartate aminotransferase (ASAT). All data are mean ± standard deviation. *P < 0.05 versus Con; †P < 0.05 versus LC (ANOVA, least significant 
difference post hoc test).R200.4 Genome Biology 2007,     Volume 8, Issue 9, Article R200       Kleemann et al. http://genomebiology.com/2007/8/9/R200
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Figure 1 (see legend on next page)
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In the LC group, most significant effects occurred within the
master process of lipid metabolism. Important subprocesses
(that is, processes in which more than 10% of process-related
genes changed significantly) were lipid biosynthesis, lipopro-
tein metabolism, cholesterol metabolism and cholesterol bio-
synthesis (Table 3). The overall functional effect of LC
treatment can be summarized as a substantial down-regula-
tion of cholesterol and lipid metabolism. This adaptive
response of the liver indicates metabolic liver resilience up to
doses of 0.25% (w/w) cholesterol.
A further increase of dietary cholesterol (1% w/w; HC group)
intensified the changes in gene expression seen with LC
treatment, indicating further metabolic adaptation. For
example, all individual genes of the cholesterol biosynthesis
pathway were down-regulated to a greater extent by HC than
by LC treatment (see pathway map in Additional data file 4a):
the gene of the rate-limiting enzyme of this pathway, HMG
CoA reductase (HDMH), was down-regulated 2.8-fold and
10.6-fold by LC and HC treatments, respectively. Similarly,
genes relevant for lipid and lipoprotein metabolism, LDL
receptor (LC group, 1.3-fold down-regulated; HC group, 1.9-
fold down-regulated) and lipoprotein lipase (LC group, 1.8-
fold up-regulated; HC group, 5.5-fold up-regulated), were
dose-dependently modulated.
Besides marked effects on 'lipid metabolism', HC treatment
induced significant changes in the master processes: 'general
metabolism', 'transport' and 'immune and inflammatory
response' (Table 3). In particular, HC treatment enhanced the
subprocesses involved in translational initiation, Golgi vesicle
transport, mitochondrial transport, antigen presentation,
antigen processing and acute phase response by affecting the
e x p r e s s i o n  o f  m o r e  t h a n  3 5 %  o f  t h e  g e n e s  i n  t h e s e
subprocesses.
Significantly, HC but not LC dietary stress activated specific
inflammatory pathways (that is, the platelet-derived growth
factor (PDGF), interferon-γ (IFNγ), interleukin-1 (IL-1) and
tumor necrosis factor-α (TNFα) signaling pathways; Figure
3). Activation of these inflammatory pathways with HC treat-
ment leads to a significant up-regulation of MAP kinases,
complement factors and acute phase proteins such as SAA.
HC treatment significantly up-regulates, for example, all four
SAA isotype genes (Figure 4a), which is consistent with the
observed changes in SAA protein concentrations in plasma
(compare Table 1).
More generally, HC treatment induced many genes, the gene
products of which reportedly or putatively initiate or mediate
inflammatory events (Additional data file 3), including genes
encoding proteases, complement components, chemokines
and their receptors, heat shock proteins, adhesion molecules
and integrins, acute phase proteins, and inflammatory tran-
scription factors, altogether indicating a profound
reprogramming of the liver towards an inflammatory state
not observed with LC treatment.
In separate experiments using female E3L mice, the hepatic
inflammatory response to cholesterol-feeding was analyzed
in more detail, including dose-dependency and time course.
Plasma SAA served as a marker and readout of liver inflam-
mation. Feeding of cholesterol at doses up to 0.50% w/w did
not alter plasma SAA levels (Figure 4b). At higher cholesterol
doses (≥0.75% w/w), plasma SAA levels increased markedly.
A time course study with 1% w/w cholesterol (HC diet)
showed that plasma SAA levels started to increase after 2
weeks and that plasma SAA levels continued to increase over
time (Figure 4c). Together, these refined analyses indicate
that the liver is resilient up to a cholesterol dose of about
0.50% w/w (adaptive response) and that the inflammatory
response evoked with higher cholesterol concentrations
starts within two weeks of starting the HC diet.
Enrichment analysis with disease categories confirmed the
activation of many signaling and effector pathways relevant
Analysis of plasma lipids and atherosclerosis Figure 1 (see previous page)
Analysis of plasma lipids and atherosclerosis. (a) Lipoprotein profiles of the Con, LC and HC groups at ten weeks. (b) Representative photomicrographs 
of cross-sections of the aortic root area. (c) Total cross-sectional lesion area in the aortic root. (d) Lesion severity of the treatment groups determined 
according to the lesion classification of the American Heart Association (I-VI). Data are presented as means ± standard deviation. *P < 0.05 versus Con; #P 
< 0.05 versus LC.
Venn diagram of significantly differentially expressed genes in the LC and  HC groups compared to the Con group Figure 2
Venn diagram of significantly differentially expressed genes in the LC and 
HC groups compared to the Con group. ANOVA P < 0.01 and FDR 
(predicted) <0.05 resulted in 2,846 probesets, and subsequent t-tests with 
P < 0.01 for HC versus Con and/or LC versus Con resulted in the 2,447 
probesets shown.
111 440 1,896
LC
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for inflammation and immunity by HC, but not by LC, treat-
ment. The most affected (that is, activated at the gene
expression level) disease categories with HC treatment were
interrelated cardiovascular disorders and (auto) immune
diseases, including cerebral and intracranial arterial diseases,
cerebral amyloid angiopathy, hepatocellular carcinoma, and
hepatitis (Additional data file 4b).
Altogether, this global analysis shows that the liver responds
to a low load of dietary cholesterol mainly by adapting its met-
abolic program, whereas at a high cholesterol load the liver is
much more extensively reprogrammed, and, in addition to
metabolic adaptations, expresses genes involved in inflam-
matory stress.
Analysis of diet-dependent metabolic changes in liver 
and plasma
To verify whether the switch from metabolic adaptation (with
LC treatment) to hepatic inflammatory stress (with HC treat-
ment) is also reflected at the metabolite level, we performed a
comprehensive HPLC/MS-based lipidome analysis (meas-
urement in total of about 300 identified di- and triglycerides,
phosphatidylcholines, lysophosphatidylcholines, cholesterol
esters) on liver homogenates of Con, LC and HC groups, and
corresponding plasma samples.
The individual metabolite fingerprints within a treatment
group were similar and formed clusters as assessed by princi-
pal component analysis (PCA; Figure 5). The clusters of the
Con and LC groups overlapped partly, demonstrating that the
Con and LC groups have a similar intrahepatic lipid pattern.
This indicates that the metabolic adjustments on the gene
level in the LC group were efficacious and enabled the liver to
cope with moderate dietary stress. The HC cluster did not
overlap with the clusters of the Con group, demonstrating
that the switch to a proinflammatory liver gene expression
profile is accompanied by development of a new metabolic
hepatic state, which differs significantly from the metabolic
state at baseline (Con group).
Identification of transcriptional regulators that control 
the hepatic response to cholesterol
To identify the transcription factors and underlying regula-
tory mechanisms that govern the hepatic response to LC and
HC stress, we performed a combined analysis of the liver
transcriptome and metabolome dataset. Functional networks
allowed the identification of transcriptional key ('master')
regulators relevant for liver resilience and liver inflammation.
The adaptation of hepatic lipid metabolism to LC stress was
mainly controlled by retinoid X receptor (RXR), SP-1, perox-
isome proliferator activated receptor-α (PPARα), sterol regu-
latory element binding protein (SREBP)1 and SREBP2
(networks not shown), which are established positive regula-
tors of genes involved in cholesterol biosynthesis [16].
Combined analysis of genome and metabolite datasets
revealed that the intrahepatic level of eicosapentaenoic acid,
a suppressor of SREBP1 [17], was increased, providing a
molecular explanation for the observed down-regulation of
genes involved in cholesterol biosynthesis (Additional data
file 5).
A subsequent network analysis of HC-modulated genes
allowed the identification of transcription factors that medi-
ate the evolution of hepatic inflammation and are ultimately
responsible for the effects on the process level. HC-evoked
changes require specific transcriptional master regulators,
some of which are established in this context (nuclear factor
kappa B (NF-κB), activator protein-1 (AP-1), CAAT/
enhancer-binding protein (C/EBP)β, p53), and others that
are new (CREB-binding protein (CBP), hepatocyte nuclear
factor-4α(HNF4α), SP-1, signal transducer and activator of
transcription-3/-5 (STAT-3/-5), Yin Yang-1 (YY1); Figure 6
and Additional data file 6).
Table 2
Overview of genes that are differentially expressed in response to cholesterol
LC HC
GO category Up Down Total Up Down Total
Lipid and lipoprotein metabolism (includes cholesterol and steroid metabolism) 8 50 58 37 114 151
Protein metabolism (includes protein folding and breakdown) 34 14 48 143 98 241
Other metabolism (includes carbohydrate metabolism) 32 19 51 122 130 252
Generation of precursor metabolites and energy 10 15 25 24 47 71
Transport 31 15 46 125 77 202
Immune and stress response/inflammation 19 7 26 99 49 148
Cell proliferation/apoptosis 9 3 12 37 18 55
Cell adhesion/cytoskeleton 10 1 11 76 8 84
Differentially expressed genes of LC and HC groups (ANOVA FDR < 0.05 and t-test compared to Con group P < 0.01) were analyzed according to 
standard GO biological process annotation and grouped into functional categories.http://genomebiology.com/2007/8/9/R200 Genome Biology 2007,     Volume 8, Issue 9, Article R200       Kleemann et al. R200.7
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Consistent with this, the identified transcription factors con-
trol the expression of genes encoding acute phase response
proteins, complement factors, growth factors, proteases,
chemokine receptors and factors stimulating cell adhesion, as
confirmed by data mining. Most importantly, HC treatment
induced genes whose products can act extracellularly (Addi-
tional data file 7) and possess reportedly pro-atherogenic
properties. Examples include complement components
(C1qb, C1qR, C3aR1, C9), chemoattractant factors (ccl6,
ccl12, ccl19), chemoattractant receptors (CCR2, CCR5),
cytokines inducing impaired endothelial barrier function
(IFN-γ), adhesion regulators (integrin β2, integrin β5, CD164
antigen/sialomucin, junction adhesion molecule-2), growth
factors (PDGF, vascular endothelial growth factor (VEGF)-C,
transforming growth factor (TGF)-β), proteases involved in
matrix remodeling during atherogenesis (cathepsins B, L, S
and Z; matrix metalloprotease-12), and cardiovascular risk
factors/inflammation markers (haptoglobin, orosomucoid 2,
fibrinogen-like protein 2, α1-microglobulin). This upregula-
tion of pro-atherogenic candidate genes in the HC group is
consistent with the observed enhanced early atherosclerosis
found in this group.
Expansion of the lipid and inflammatory networks revealed
that hepatic lipid metabolism is linked to the hepatic
inflammatory response via specific transcriptional regulators
that control both processes. Among these dual regulators
were CBP, C/EBPs, PPARα and SP-1 (Table 4). The presence
of molecular links between lipid metabolism and inflamma-
tion raises the possibility that specific intervention with an
anti-inflammatory compound may, in turn, affect plasma
cholesterol levels. In a first attempt to test this possibility,
female E3L mice were fed a HC diet to increase plasma cho-
lesterol levels (from 5.3 mM to 19.3 mM) and systemic
inflammation (SAA from 1.7 μg/ml to 9.2 μg/ml). Then, ani-
mals were treated with the same HC diet supplemented with
salicylate, an inhibitor of NF-κB signaling, or vehicle. While
plasma cholesterol and SAA levels remained elevated in the
vehicle-treated group, the salicylate-treated group displayed
significantly lower plasma SAA levels (7.7 μg/ml; P < 0.05)
and significantly reduced cholesterol levels (9.9 mM; P  <
0.05) demonstrating that specific intervention into the
inflammatory component does indeed affect plasma
cholesterol.
Table 3
Analysis of processes that are changed significantly upon treatment with dietary cholesterol
Differentially expressed (%)
Master process Subprocess (child terms) Number of genes measured LC HC
Lipid metabolism 264 8.7* 24.2*
Fatty acid metabolism, fatty acid beta-oxidation 8 0.0 50.0*
Triacylglycerol metabolism 7 0.0 57.1*
Cholesterol metabolism 27 33.3* 33.3*
Cholesterol biosynthesis 7 71.4* 57.1*
Lipoprotein metabolism 18 16.7* 44.4*
Lipid biosynthesis 105 11.4* 23.8*
Immune response 297 3.0 12.1*
Antigen presentation, exogenous antigen 10 10.0 70.0*
Antigen processing 17 5.9 35.3*
Acute-phase response 11 9.1 36.4*
General metabolism 3,600 3.3 13.1*
Cellular polysaccharide metabolism 19 5.3 26.3*
Polysaccharide biosynthesis 9 0.0 33.3*
Cofactor metabolism 116 5.2 21.6*
Regulation of translational initiation 9 0.0 44.4*
Amino acid metabolism 103 2.9 20.4*
Transport 1,119 2.9 14.3*
Intracellular protein transport 161 3.7 19.9*
Golgi vesicle transport 16 6.3 37.5*
Mitochondrial transport 11 18.2* 54.5*
Master processes and their subprocesses (child terms) are listed together with the number of genes measured (third column). Percentages reflect the fraction of genes 
differentially expressed (within a specific process or pathway) in the LC and HC groups compared to the Con group. Relevant biological processes were identified in GenMAPP 
by comparison of the set of differentially expressed genes (ANOVA; P < 0.01 and FDR < 0.05) with all genes present on the array. *Biological processes with a Z-score >2 and 
a PermuteP < 0.05.R200.8 Genome Biology 2007,     Volume 8, Issue 9, Article R200       Kleemann et al. http://genomebiology.com/2007/8/9/R200
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Figure 3 (see legend on next page)
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Discussion
Development of atherosclerotic lesions requires a lipid com-
ponent (hypercholesterolemia) and an inflammatory compo-
nent. In the present study, we demonstrate that high dose
dietary cholesterol (HC diet) strongly induces early athero-
sclerotic lesion formation in a humanized model for
atherosclerosis, E3L mice. This is not, or is only slightly, the
case with a cholesterol-free (Con) or low dose cholesterol (LC)
diet. Importantly, Con, LC, and HC diets dose-dependently
increase plasma cholesterol levels, but only HC treatment
induces a marked systemic inflammatory response, which
precedes lesion formation and is related to liver inflamma-
tion. We employed newly developed (functional) systems
biology technologies to unravel how increasing the dose of
dietary cholesterol affects liver homeostasis and evokes
hepatic inflammation. The following important findings were
made. The liver absorbs escalating doses of dietary
cholesterol primarily by adjusting the expression level of
genes involved in lipid metabolism, as revealed by advanced
gene expression analysis. This metabolic resilience is con-
firmed by analysis of metabolites in liver. At high doses of die-
tary cholesterol, the liver also develops an inflammatory
stress response, which is characterized by up-regulation of
pro-atherogenic candidate genes and activation of (at least
four distinct) inflammatory pathways. The evolution of
hepatic inflammation involves specific transcriptional regula-
tors, several of which have been newly identified in this study.
Interestingly, some of these transcription factors have a dual
role and control both hepatic lipid metabolism and hepatic
inflammation, indicating that the same regulatory mecha-
nisms underlie these processes and thereby link the two
processes.
The present study delineates, to our knowledge for the first
time, the genome-wide response of the liver to increasing
doses of dietary cholesterol, with specific attention to inflam-
matory processes, and in relation to early atherosclerotic
lesion formation. The liver responds to moderate elevations
in dietary cholesterol (LC diet) by adjusting major metabolic
processes related to lipid metabolism. For example, the
expression of genes involved in endogenous cholesterol syn-
thesis (for example, HMG-CoA reductase) and cholesterol
uptake from plasma (for example, LDLR) is diminished. At
high loads of dietary cholesterol (HC diet), the liver strives for
homeostasis by intensifying the changes in gene expression
observed with the LC diet. Similar dose-dependent effects of
dietary cholesterol have been reported by others [18] but the
number of studies that assess dose-dependent effects of die-
tary cholesterol is relatively small and analyses are restricted
to a limited number of genes. Our genome-wide approach is
comprehensive and demonstrates that metabolic processes as
a whole are adjusted at the level of gene expression.
Importantly, the adjustment at the gene level is efficacious
only up to a certain degree of cholesterol stress: while low
loads of cholesterol are fully absorbed (consider the compara-
ble intrahepatic lipidome fingerprints for the LC and Con
groups), exposure to high loads of dietary cholesterol in the
HC group significantly altered the liver lipidome, despite
further intensified adjustment of gene expression. Our com-
bined analysis of genes and functional readouts (lipid metab-
olites) clearly demonstrates t h a t  a  d o s e  o f  1 %  w / w  o f
cholesterol, which is typically used to induce experimental
dyslipidemia and atherosclerosis in mice [13,19,20], is an
extreme condition because the metabolic resilience of the
liver is already overstretched.
Concomitant with the adjustment of metabolic genes to HC
dietary stress, HC treatment also evokes a hepatic inflamma-
tory response. The development of an inflammatory gene
expression profile upon feeding of a diet containing choles-
terol has also been reported by others. For example, Tous et
al. [21] showed that atherosclerosis-prone apoE-/- mice
receiving a high fat/high cholesterol diet develop an impair-
ment of liver histology consisting of fat accumulation, macro-
phage proliferation, and inflammation, and that there is a
chronological and quantitative relationship between liver
impairment and the formation of atheromatous lesions.
Vergnes et al. [22] showed that cholesterol and cholate com-
ponents of the atherogenic diet have distinct pro-atherogenic
effects on gene expression and particularly that cholesterol is
required for induction of genes involved in acute inflamma-
tion in C57BL/6J mice. Recinos et al. [23] reported that liver
gene expression in LDLR-/- mice is associated with diet and
lesion development and demonstrated the induction of com-
ponents of the alternative component pathway. Zabalawi et
al. [24] showed the induction of fatal inflammation in LDLR-
/- and ApoAI-/-LDLR-/- mice fed dietary fat and cholesterol.
However, the exact molecular inflammatory pathways
switched on/off by dietary cholesterol have remained
unknown. While some of the above studies employing
microarray analysis have examined some of the individual
components of the inflammatory response to cholesterol, we
have set out to generate a holistic profile of the complex,
Analysis of the inflammatory pathways activated by the LC and HC diets Figure 3 (see previous page)
Analysis of the inflammatory pathways activated by the LC and HC diets. A master inflammatory network was generated in MetaCore™ by combining 
relevant inflammatory pathways. Differentially expressed genes in response to (a) LC and (b) HC treatment were mapped into this master network. The 
activation of the network by LC treatment was minimal, whereas HC treatment resulted in a profound activation of specific proinflammatory pathways 
(marked with blue arrows). Red circles indicate transcriptional node points and red rectangles highlight representative downstream target genes that were 
up-regulated.R200.10 Genome Biology 2007,     Volume 8, Issue 9, Article R200       Kleemann et al. http://genomebiology.com/2007/8/9/R200
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interrelated nature of the response of the liver to cholesterol.
Advanced pathway analysis combined with functional net-
work building enabled us to unravel four key inflammatory
pathways (IFNγ, TNFα, IL-1, and PDGF pathways) that play
central roles in the evolution of cholesterol-induced inflam-
mation in the liver. Further research is necessary to resolve
the sequence of events over time (for example, which pathway
is switched on first). Remarkably, these pathways are also
critical for lesion development in the vessel wall, suggesting
that the inflammatory response to cholesterol stress
described herein for the liver may involve similar routes in
other tissues and, as such, has more general significance.
Our results suggest that hepatic inflammatory response may
be causatively related to lesion initiation in the aorta, because
pro-atherogenic candidate genes (that is, genes encoding can-
didate inflammatory components reportedly or putatively
involved in early lesion formation) were found to be upregu-
lated specifically in the HC group but not, or only slightly, in
the LC group. The presence of a 'hepatic source' for inflamma-
tory factors in HC stress may also explain the observed expo-
nential (rather than linear) increase in lesion formation seen
with increasing dietary cholesterol loads [11,12]. Consistent
with this notion is the view that the inflammatory arm of
atherogenesis is a principle driving force of lesion
development.
An inflammatory reprogramming of the liver has also been
Expression of SAA genes Figure 4
Expression of SAA genes. (a) All four isotype genes were dose-
dependently increased with increasing dietary cholesterol exposure. 
*Significant compared to Con, P < 0.01. (b) Plasma SAA levels in response 
to increasing doses of dietary cholesterol. Female E3L animals (n ≥ 7/
condition) were fed the Con diet supplemented with increasing 
concentrations of cholesterol for 10 weeks. *P < 0.05 versus 0% w/w 
cholesterol control group. (c) Plasma SAA levels in the HC diet (1% w/w 
cholesterol) fed female E3L animals (n = 8) over time. *P < 0.05 versus t = 
0.
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Lipidom analysis of liver homogenates (n = 10 per group) Figure 5
Lipidom analysis of liver homogenates (n = 10 per group). Score plot was 
derived from PCA. The two component model explained 36.6% (principle 
component 1; PC# 1) and 24.4% (PC# 2) of the variation in the data.
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Representative biological network based on differentially expressed genes of the HC group using MetaCore™ network software and the Analyze  Network algorithm Figure 6 (see following page)
Representative biological network based on differentially expressed genes of the HC group using MetaCore™ network software and the Analyze 
Network algorithm. Two representative networks are shown: (a) the C/EBPβ c-jun network and (b) the NF-κB network. A legend for the biological 
networks is provided in Additional data file 7d. Red dots in the right corner of a gene indicate up-regulation and blue dots down-regulation.http://genomebiology.com/2007/8/9/R200 Genome Biology 2007,     Volume 8, Issue 9, Article R200       Kleemann et al. R200.11
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Figure 6 (see legend on previous page)
(a)
(b)R200.12 Genome Biology 2007,     Volume 8, Issue 9, Article R200       Kleemann et al. http://genomebiology.com/2007/8/9/R200
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observed in C57BL/6J mice treated with a 1.25% w/w choles-
terol diet resulting in total plasma cholesterol concentrations
of 3.6 mM [22], that is, a level comparable to the Con group
in our study. Unlike that in E3L mice, the total plasma choles-
terol in C57BL/6J mice is mainly confined to HDL, an anti-
atherogenic, anti-inflammatory lipoprotein facilitating trans-
port of cholesterol from the periphery back to the liver. The
fact that mice with a strongly different lipoprotein profile
(E3L, LDLR-/- and C57BL/6) show a similar hepatic inflam-
matory response to cholesterol feeding indicates that the
observed inflammatory effect of dietary cholesterol is a gen-
eral phenomenon and not restricted to the model of dysbetal-
ipoproteinemia used herein. Also, it suggests that the influx of
dietary cholesterol into the liver (via chylomicrons) rather
than plasma cholesterol is key to the inflammatory response
of the liver. This supposition would also be in accord with the
rapidity of the effect: in a time-resolved analysis of plasma
SAA during atherogenesis, we report here a strong elevation
of plasma SAA within two weeks of cholesterol-feeding in
female E3L mice. This is also in line with the inflammatory
reprogramming of C57BL6/J mice within three weeks [22]
and clearly demonstrates that the hepatic inflammatory
response precedes the formation of atherosclerotic lesions,
suggesting that dietary cholesterol can be an important trig-
ger and a possible source of the inflammatory component of
atherosclerotic disease. In the present study, the liver func-
tion markers ALAT and ASAT remained within the normal
levels stipulated for the function criteria for donor livers [25],
indicating normal liver function under the experimental con-
ditions applied in this study. Our results do not exclude the
possibility, however, that sterols may oxidize and become
toxic and that the oxidized sterols contribute, at least partly,
to the inflammatory effects observed by us and others.
Inflammation may also arise from established risk factors
other than high plasma cholesterol (for example, hyperten-
sion, diabetes/hyperglycemia). Dietary glucose can modulate
the mRNA expression and serum concentrations of immune
parameters but these alterations rapidly normalize in normo-
glycemic subjects [26]. In the case of an impaired metabolic
state, however, postprandial hyperglycemia increases the
magnitude and duration of systemic inflammatory responses,
which probably promotes the development of cardiovascular
disease.
Our results show that the evolution of hepatic inflammation
is controlled by specific transcriptional regulators, some of
which are well known in the context of cholesterol-inducible
inflammation (SREBPs, NF-κB, AP-1, C/EBPs), while others
have been newly identified in the present study (CBP,
HNF4α, SP-1, STAT-3/-5, YY1). Interestingly, some of these
factors may also represent molecular links between lipid/cho-
lesterol metabolism and inflammation. Supportive evidence
for an interrelationship between liver metabolism and
inflammation also comes from pharmacological intervention
studies. On the one hand, cholesterol-lowering drugs reduce
the general inflammatory status and the expression of liver-
derived inflammation markers in E3L mice (compare to the
pleiotropic effects of statins) [7,14,27] The anti-inflammatory
IKKβ-inhibiting compound salicylate [28,29] reduces plasma
Table 4
Identified master regulators that control inflammatory reprogramming of the liver
Transcription factor Regulator of/node point for Example of downstream effects
AP-1 (c-jun/c-fos) Inflammation Mmp-12, col1a1, hsp27
CREP binding protein (CBP) Lipid, inflammation, immune response, cell 
proliferation
Very broadly acting coactivator (can bind to SREBPs)
C/EBPs Lipid, inflammation, energy metabolism Acute phase genes (for SAA, CRP, fibrinogen), hepatic 
gluconeogenesis and lipid homeostasis, energy 
metabolism (PEPCK, FAS), TGF-β signaling
Forkhead transcription factor FOXO1 Lipid, inflammation/proliferation Glycolysis, pentose phosphate shunt, and lipogenic and 
sterol synthetic pathways, LPL (via SHP)
NF-κB Inflammation SAA, CD83, CD86, CCR5, VEGF-C
PPARα/RXRα Lipid, inflammation LPL, ABCA1, macrophage activation, glucose 
homeostasis
p53 Inflammation HSP27, HSPA4, IFI16, IBP3, RBBP4
SMAD3 Inflammation Proteases and growth factors (via TGF-β signaling)
SP-1 Lipid, inflammation ABCA1, ICAM-1, cellular matrix genes COL1A1, 
COL1A2
SREBP-1/-2 Lipid, inflammation Sterol biosynthesis genes, LDLR, link to C/EBPα
STAT1/3/5 Inflammation Acute phase genes
YY1 Inflammation/proliferation Inflammatory response genes (SAA, vWF, CCR5), cellular 
matrix genes
Biological networks were generated using MetaCore™ software and transcriptional master regulators were identified in significant gene networks (P 
< 0.05).http://genomebiology.com/2007/8/9/R200 Genome Biology 2007,     Volume 8, Issue 9, Article R200       Kleemann et al. R200.13
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cholesterol in the same mouse model (this paper) indicating
that modulation of cholesterol levels via inflammation may be
possible as well. A hypocholesterolemic effect of salicylate has
also been reported in catfish [30] and salicylate was found to
inhibit hepatic lipogenesis in isolated rat hepatocytes in vitro
[31]. Prigge and Gebhard [32] showed that acetylsalicylate
(aspirin), a classical inhibitor of COX1 and COX2 [29],
induces biliary cholesterol secretion in the rat, an effect that
may contribute to the cholesterol-lowering effect seen with
compounds of the salicylate category: in diabetic human sub-
jects, very high doses of aspirin (around 7 g/d) were associ-
ated with a 15% reduction of total plasma cholesterol and CRP
[29].
Conclusion
We demonstrate that dietary cholesterol is not only a lipid
risk factor but also a trigger of hepatic inflammation and, as
such, also involved in the evolution of the inflammatory arm
of atherosclerotic disease. A certain degree of genetic resil-
ience and elasticity allows the liver to cope with moderate
cholesterol stress, but high loads of cholesterol result in an
inflammatory pro-atherogenic response (involving specific
pathways and transcriptional regulators), which enhances
early lesion formation. Our findings that cholesterol and
inflammation are closely linked via specific transcriptional
master regulators might lead to new strategies for future ther-
apeutic intervention.
Materials and methods
Animals and diets
Female E3L mice were used at the age of 12 weeks for all
e x p e r i m e n t s .  A n i m a l  e x p e r i m e n t s  w e r e  a p p r o v e d  b y  t h e
Institutional Animal Care and Use Committee of The Nether-
lands Organization for Applied Scientific Research (TNO)
and were in compliance with European Community specifica-
tions regarding the use of laboratory animals.
A group of E3L mice (n = 17) was treated with a cholesterol-
free diet (diet T; Hope Farms, Woerden, The Netherlands) for
10 weeks (Con group). The major ingredients of diet T (all w/
w) were cacao butter (15%), corn oil (1%), sucrose (40.5%),
casein (20%), corn starch (10%) and cellulose (6%). Two
other groups (n = 17 each) received the same diet but supple-
mented with either 0.25% w/w cholesterol (LC group) or 1.0%
w/w cholesterol (HC group). After ten weeks of diet feeding,
animals were euthanized under anesthesia to collect livers,
hearts and aortas. Tissues were snap-frozen in liquid nitrogen
and stored at -80°C until use.
To assess the effect of salicylate on plasma levels of inflamma-
tion markers and cholesterol, two groups of female E3L mice
(n = 10; 12 weeks old) were treated with the HC diet for 3
weeks. Then, HC dietary treatment was either continued
(vehicle control group) or animals were fed HC supplemented
with 0.12% w/w salicylate (equaling a dose of 145 mg/kg/day)
for 8 weeks. Plasma samples were obtained by tail bleeding
without fixation of the test animals to minimize stress.
Analyses of plasma lipids and proteins
Total plasma cholesterol and triglyceride levels were meas-
ured after 4 h of fasting, using kits No.1489437 (Roche Diag-
nostics, Almere, The Netherlands) and No.337-B (Sigma,
Aldrich Chemie BV, Zwijndrecht, The Netherlands) [33]. For
lipoprotein profiles, pooled plasma was fractionated using an
KTA FPLC system (Pharmacia, Roosendaal, The Nether-
l a n d s )  [ 9 ] .  T h e  p l a s m a  l e v e l s  o f  S A A  w e r e  d e t e r m i n e d  b y
ELISA as reported [14]. Plasma ALAT and ASAT levels were
determined spectrophotometrically using a Reflotron system
(Roche Diagnostics) [9].
For lipiodomics analysis of liver homogenates and plasma
samples, electrospray liquid chromatography mass spectros-
copy (LC-MS) analysis was applied [34]. Briefly, samples (5
μl) were incubated with 200 μl isopropanol and a mixture of
internal standards (heptadecanoyl-lysophosphatidylcholine,
di-lauroyl-phosphatidylcholine, heptadecanoyl-cholesterol
and tri-heptadecanoyl-glycerol; Sigma, St Louis, MO, USA)).
After vortexing, the lipids were extracted and isolated by cen-
trifugation (lipids in isopropanol phase). Electrospray LC-MS
lipid analysis was performed on a Thermo LTQ apparatus
equipped with a Surveyor HPLC system (Thermo Electron,
San Jose, CA, USA). The samples were measured in fully ran-
domized sequences. Quality control samples, prepared from a
single pool of E3L mouse reference tissue, were analyzed at
regular intervals (bracketing 10 samples). The LC-MS raw
data files were processed using a software developed by TNO
(IMPRESS) to generate comprehensive peak tables (m/z
value, retention time and peak area). Data were then sub-
jected to retention time alignment of peaks, internal standard
correction of peak areas and quality control resulting in a
final lipidomics dataset.
The obtained lipidomics dataset was analyzed and visualized
by PCA essentially as described [35]. Prior to analysis, the
data were mean-centered and auto-scaled to ensure an equal
contribution of all lipid measurements to the PCA-model.
Analyses of atherosclerosis
Hearts were fixed and embedded in paraffin to prepare serial
cross sections (5 μm thick) throughout the entire aortic valve
area for (immuno) histological analysis. Cross sections were
stained with hematoxylin-phloxine-saffron, and
atherosclerosis was analyzed blindly in four cross-sections of
each specimen (at intervals of 30 μm) as reported [14,36].
QWin-software (Leica) was used for morphometric
computer-assisted analysis of lesion number, lesion area, and
lesion severity as described in detail elsewhere [7]. Signifi-
cance of difference was calculated by one-way analysis of var-
iance (ANOVA) test followed by a least significant difference
post hoc analysis using SPSS 11.5 for Windows (SPSS, Chi-R200.14 Genome Biology 2007,     Volume 8, Issue 9, Article R200       Kleemann et al. http://genomebiology.com/2007/8/9/R200
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cago, IL, USA). The level of statistical significance was set at
α < 0.05.
Nucleic acid extraction and gene expression analysis
Total RNA was extracted from individual livers (n = 5 per
group) using RNAzol (Campro Scientific, Veenendaal, The
Netherlands) and glass beads according to the manufacturer's
instructions. The integrity of each RNA sample obtained was
examined by Agilent Lab-on-a-chip technology using the
RNA 6000 Nano LabChip kit and a bioanalyzer 2100 (both
Agilent Technologies, Amstelveen, The Netherlands). The
quality control procedure is described in Additional data file
8. The One-Cycle Target Labeling and Control Reagent kit
(Affymetrix #900493) and the protocols optimized by
Affymetrix were used to prepare biotinylated cRNA (from 5
μg of total RNA) for microarray hybridization (n  = 5 per
group). The quality of intermediate products (that is, biotin-
labeled cRNA and fragmented cRNA) was again controlled
using the RNA 6000 Nano Lab-on-a-chip and bioanalyzer
2100. Microarray analysis was carried out using an Affyme-
trix technology platform and Affymetrix GeneChip® mouse
genome 430 2.0 arrays (45,037 probe sets; 34,000 well-char-
acterized mouse genes). Briefly, fragmented cRNA was mixed
with spiked controls, applied to Affymetrix Test chips, and
good quality samples were then used to hybridize with
murine GeneChip® 430 2.0 arrays. The hybridization, probe
array washing and staining, and washing procedures were
executed as described in the Affymetrix protocols, and probe
arrays were scanned with a Hewlett-Packard Gene Array
Scanner (Leiden Genome Technology Center, Leiden, The
Netherlands).
Gene expression data analysis
Raw signal intensities were normalized using the GCRMA
algorithm (Affylm package in R). Datasets are freely accessi-
ble online through ArrayExpress [37]. Normalized signal
intensities below 10 were replaced by 10. Probe sets with an
absent call in all arrays were removed before further analysis
of the data. RT-PCR was performed essentially as described
[27,38] to validate and confirm differences in gene expression
between the treatment groups.
Statistical analysis was performed in BRB ArrayTools (Dr
Richard Simon and Amy Peng Lam [39]). Con, LC and HC
groups were tested for differentially expressed genes using
class comparisons with multiple testing corrections by esti-
mation of false discovery rate (FDR). Differentially expressed
genes were identified at a threshold for significance of α <
0.01 and a FDR < 5%. Within the set of differentially
expressed genes, a Student's t-test was carried out to analyze
differential expression of individual genes between the cho-
lesterol-fed groups and the Con group. Differences of P < 0.01
versus Con were considered significant.
For biological interpretation of the differentially expressed
genes, software tools GenMAPP and MetaCore™ (GeneGo
Inc., St Joseph, MI, USA) were used. Enrichment of biological
processes (GO annotation) was analyzed in GenMAPP, bio-
logical processes in GenMAPP with a Z-score >2 and Per-
muteP < 0.05 were considered as significantly changed. In
MetaCore™, enrichment analysis [40] of four independent
ontologies was performed. In addition to biological process
gene ontology, data were also analyzed in canonical pathway
maps, GeneGo-cellular processes and disease categories.
Distribution by canonical pathway maps reveals the most sig-
nificant signaling and/or metabolic pathways. Experimental
data are visualized as red/blue thermometers pointing up/
down, and signifying up/down-regulation of the map objects.
Distribution by GeneGo processes provides the most signifi-
cant functional process categories enriched with experimen-
tal data. GeneGo processes represent comprehensive pre-
built process-specific networks, in which all objects are
interconnected by experimentally validated interactions. The
up- and down-regulated genes are visualized as red or blue
circles, respectively. The disease categories represent sets of
genes associated with certain diseases. Gene enrichment
analysis shows the relative enrichment of the up- and down-
regulated genes with the genes from different disease catego-
ries. As in the case of process enrichment, this procedure is
carried out by p value distribution.
The biological networks were assembled from manually
curated protein-protein, protein-DNA and protein-ligand
(metabolite) interactions, which are accumulated in the Met-
aCore™ database. Each edge or link on the network is based
on small-experiment data referenced in the corresponding
literature. The legend for MetaCore™ Networks from the
MetaCore™ guideline is provided in Additional data file 6d.
For the generation of functional networks, transcriptome and
metabolome datasets were merged, allowing combined anal-
ysis. Networks were generated using the Shortest path (SP)
algorithm, which links the nodes from experimental datasets
by the shortest directed graphs, allowing up to two additional
steps using interactions and nodes from the MetaCore™
database. To present most of the relevant network data on the
same figure, we used the add/expand function and the Merge
Networks feature. The resulting networks provide links based
on the known interaction data not only between the nodes
from the query data set(s), but also between the nodes that
regulate the given genes or metabolites. Network nodes with
available experimental data are distinguished with red or blue
circles, representing up- or down-regulation, respectively.
Abbreviations
ALAT, alanine aminotransferase; AP, activator protein;
ASAT, aspartate aminotransferase; CBP, CREB-binding pro-
tein; C/EBP, CAAT/enhancer-binding protein; Con, choles-
terol-free; CRP, C-reactive protein; E3L, ApoE*3Leiden
transgenic; FDR, false discovery rate; GO, Gene Ontology;
HC, high-cholesterol; HDL, high-density lipoprotein; HNF,http://genomebiology.com/2007/8/9/R200 Genome Biology 2007,     Volume 8, Issue 9, Article R200       Kleemann et al. R200.15
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hepatocyte nuclear factor; IFN, interferon; IL, interleukin;
LC, low-cholesterol; LC-MS, liquid chromatography mass
spectroscopy; LDL, low-density lipoprotein; NF-κB, nuclear
factor kappa B; PCA, principal component analysis; PDGF,
platelet-derived growth factor; PPAR, peroxisome prolifera-
tor activated receptor; RXR, retinoid X receptor; SAA, serum
amyloid A; SREBP, sterol regulatory element binding pro-
tein; STAT, signal transducer and activator of transcription;
TGF, transforming growth factor; TNF, tumor necrosis fac-
tor; VLDL, very low-density lipoprotein; YY, Yin Yang.
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The following additional data are available with the online
version of this paper. Additional data file 1 shows the expo-
nential positive correlation between atherosclerotic lesion
area and total plasma cholesterol in female E3L mice. Addi-
tional data file 2 shows the validation and confirmation of
Affymetrix microarray gene expression data by RT-PCR
analysis. Additional data file 3 is a table of the genes (includ-
ing GenBank identification number and the gene symbol)
that are differentially expressed with increasing doses of die-
tary cholesterol. Additional data file 4 shows the canonical
pathway analysis for cholesterol metabolism and analysis of
the gene expression data based on GO annotation with dis-
ease categories (MetaCore™ software, GeneGO). Additional
data file 5 shows the comprehensive network analysis (func-
tional OMICs analysis) by merging gene expression datasets
with the metabolite datasets using MetaCore™ network soft-
ware. Additional data file 6 shows the biological networks of
differentially expressed genes in the HC group allowing the
identification of transcriptional master regulators. Additional
data file 7 is a table lisitng cholesterol-induced factors with
reported extracellular function. Additional data file 8
describes the quality control analysis steps for RNA samples
prior to hybridization on Affymetrix microarrays usig Agilent
Lab-on-a-chip technology.
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